Chugai Pharmaceutical Co., Ltd. (CHGCY)
- Previous Close
15.85 - Open
15.29 - Bid --
- Ask --
- Day's Range
15.29 - 15.94 - 52 Week Range
12.88 - 22.61 - Volume
56,453 - Avg. Volume
182,977 - Market Cap (intraday)
52.356B - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
24.86 - EPS (TTM)
0.64 - Earnings Date Jul 25, 2024
- Forward Dividend & Yield 0.27 (1.69%)
- Ex-Dividend Date Dec 28, 2023
- 1y Target Est
--
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
www.chugai-pharm.co.jp7,604
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CHGCY
Performance Overview: CHGCY
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CHGCY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CHGCY
Valuation Measures
Market Cap
52.13B
Enterprise Value
47.21B
Trailing P/E
24.83
Forward P/E
23.09
PEG Ratio (5yr expected)
7.00
Price/Sales (ttm)
7.82
Price/Book (mrq)
4.93
Enterprise Value/Revenue
7.08
Enterprise Value/EBITDA
16.52
Financial Highlights
Profitability and Income Statement
Profit Margin
31.50%
Return on Assets (ttm)
15.01%
Return on Equity (ttm)
21.20%
Revenue (ttm)
1.04T
Net Income Avi to Common (ttm)
326.37B
Diluted EPS (ttm)
0.64
Balance Sheet and Cash Flow
Total Cash (mrq)
764.57B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
287.75B
Research Analysis: CHGCY
Company Insights: CHGCY
CHGCY does not have Company Insights